Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03611075 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Scales for Repetitive and Restricted Behaviors in Children, Adolescents, and Adults With Autism Spectrum Disorder (ASD)
A Phase 1 study of Autism Spectrum Disorder, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 144
- Enrollment target
- 18
- Study locations
NCT03611075 is a Phase 1 study of Autism Spectrum Disorder that has completed, run by Hoffmann-La Roche. The registered enrollment target is 144 participants, roughly in line with the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target. The trial reports 18 study locations across 12 states.
The verdict
NCT03611075, a Phase 1 study of Autism Spectrum Disorder, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 144 participants
- Enrollment target
- 18
- Study locations
Study Summary
This is a non-drug study seeking to characterize different scales to measure repetitive and restrictive behaviors in different ASD sub-populations over time. This study will also explore the use of digital biomarkers.
Conditions Studied
Interventions
- OTHER No Intervention
Study Locations (18)
Texas
- BioBehavioral Research of Austin, PC - Austin
- Red Oak Psychiatry Associates, PA - Houston
- Road Runner Research Ltd - San Antonio
California
- PCSD Feighner Research - San Diego
- Stanford University School of Medicine - Stanford
New York
- Nathan S. Kline Institute for Psychiatric Research - Orangeburg
- Albert Einstein College of Medicine - The Bronx
Washington
- Northwest Clinical Research Center - ClinEdge - PPDS - Bellevue
- Seattle Children's Hospital - PIN; Investigational Drug Services - Seattle
Other
- Gartnavel Royal Hospital; Mental Health & Wellbeing - Glasgow
- Kings College London - London
Alabama
- Harmonex Neuroscience Research - Dothan
Arizona
- Southwest Autism Research and Resource Center - Phoenix
Florida
- Clinical Neuroscience Solutions Inc; Jacksonville Clinic - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2018-08-13 |
| Est. Completion | 2020-05-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03611075
The ClinicalTrials.gov registry entry for NCT03611075 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 144 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Autism Spectrum Disorder appearing as the primary indexed condition, and to 1 intervention - of which No Intervention is the first listed.
NCT03611075 reports 18 study locations spanning 12 distinct geographic areas - top geographies include Texas, California, New York.
Frequently Asked Questions
What is clinical trial NCT03611075 about?
NCT03611075 is a clinical study titled "A Study to Evaluate Scales for Repetitive and Restricted Behaviors in Children, Adolescents, and Adults With Autism Spectrum Disorder (ASD)". This is a non-drug study seeking to characterize different scales to measure repetitive and restrictive behaviors in different ASD sub-populations over time. This study will also explore the use of digital biomarkers.
What is the current status of trial NCT03611075?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 144 participants. The study started on 2018-08-13. Estimated completion is 2020-05-21.
What conditions does trial NCT03611075 study?
This clinical trial studies the following conditions: Autism Spectrum Disorder.
What interventions are being tested in trial NCT03611075?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT03611075?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03611075 being conducted?
This trial has 18 study locations across Alabama, Arizona, California, Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autism Spectrum Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cannabidiol (CBD) in Adults With ASD
RECRUITING · Phase 1
-
Combination Probiotic: BB-12 With LGG (Different Doses) in Treating Children With Autism Spectrum Disorder
RECRUITING · Phase 1
-
Adia MED of Winter Park LLC Autism Spectrum Disorder Research Study
RECRUITING · Phase 1
-
Safety, Tolerability and Pharmacokinetics of Lumateperone in Pediatric Patients With Autism Spectrum Disorder
RECRUITING · Phase 1
-
Autologous Umbilical Cord Blood Infusion for Children With Autism Spectrum Disorder (ASD)
COMPLETED · Phase 1
-
Study of the Pharmacokinetics and Safety of Tasimelteon in Children and Adolescents
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.